Real-world effectiveness of single-dose tafenoquine for P. vivax relapse prevention confirmed in retrospective observational study in Brazil The Lancet Infectious Diseases published operational real-world effectiveness data confirming the public health and patient benefits of using quantitative G6PD testing and tafenoquine in P. vivax malaria case management in Brazil. 5 March 2024
MMV delivers statements at the 154th session of the World Health Organization’s Executive Board MMV contributes to the Board’s debate on maternal and child health, antimalarial drug resistance, and climate change and health 29 January 2024
A message from MMV's CEO, David Reddy: Standing united in the drive to eradicate malaria To quote the eminent Chinese scientist Dr. Tu Youyou: “Every scientist dreams of doing something that can help the world.” 14 December 2023
Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings. 27 November 2023
MMV congratulates Professor David Fidock, new President-Elect of ASTMH MMV is delighted to hear of Dr. David Fidock’s selection as President-Elect of The American Society of Tropical Medicine and Hygiene (ASTMH). 13 November 2023
MMV leadership to change in 2024 After more than a decade of dedicated service, our CEO, Dr David Reddy, will be stepping down from his role to take on a new position as Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in April 2024. 6 November 2023
First African-manufactured combination therapy for seasonal malaria chemoprevention receives WHO prequalification 6 November 2023 Universal Corporation Ltd (UCL), a Strides Pharma Science Limited (Strides) enterprise, with support from MMV, has become the first African manufacturer to gain WHO prequalification for their sulfadoxine-pyrimethamine + amodiaquine product.
Trends in Parasitology: MMV in the Best of 2022 collection MMV is pleased to share that an article co-authored by Dr Didier Leroy, one of our Senior Directors for Drug Discovery, has been selected as one of the top 10 most cited and influential articles of 2022 by Trends in Parasitology. 11 October 2023
7 MMV funded scholars will start their training at the Malaria Research and Training Center, Mali This September, the first seven beneficiaries of the Ogobara K. Doumbo scholarship fund started a three-month internship at the Malaria Research and Training Center in Mali. 2 October 2023
SMC and RTS,S vaccine in combination show considerable advantage in preventing malaria SMC and the RTS,S vaccine in combination provide significant added protection against malaria in young children during the malaria season, as compared to either intervention alone. 31 August 2023
MMV launches call for compounds to accelerate research into new drugs for malaria MMV is seeking new chemical compounds to screen against malaria through its MMV open innovation (MMVoi) initiative. 30 August 2023
Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria 21 August 2023
MMV receives rank of “very high performer” in 2023 Global Health 50/50 report for 2nd year 27 July 2023
MMV awards Dr Stephen Brand-led team for developing innovative dose prediction tool 'MMVSola' 27 June 2023
Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria 6 June 2023
MMV echoes Swiss Malaria Group's call to invest and innovate to end malaria Raphealny/Pixabay 25 April 2023
MMV mourns the loss of Pascoal Mocumbi, former Mozambican prime minister and EDCTP High Representative 31 March 2023
MMV welcomes appointment of Dr Daniel Ngamije as Director of Global Malaria Control Programme 29 March 2023